Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash

15 Jun 2016

• By Mandy Jackson

microscope

Related Content

Infinity will not go beyond Phase II with retaspimycin

26 Sep 2013

Infinity PhII results a blow for PI3K in inflammation

09 Jan 2015

AbbVie outdoes rumored J&J bid with $21bn Pharmacyclics buy

05 Mar 2015

Infinity's horizons broaden with rich AbbVie co-development deal

04 Sep 2014

Venclexta Win Broadens AbbVie/Genentech CLL Positions

12 Apr 2016

Infinity cuts 20% of workforce as it refocuses on PI3K and retaspimycin

09 Aug 2012

Infinity minus one: shares plummet as spiky saridegib fails in pancreatic cancer

30 Jan 2012

Related Companies

Infinity Pharmaceuticals, Inc.

AbbVie Inc.

Roche Holding AG

Gilead Sciences, Inc.

Genentech, Inc.

Pharmacyclics, Inc.

Novartis AG

Additional Topics

Companies Clinical Trials Business Strategies

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.